EMA Refused: Nerventra (laquinimod) — Teva Pharma GmbH

View source ↗

Summary

EMA refused Teva's Nerventra (laquinimod) application for multiple sclerosis, indicating a negative regulatory decision.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Nerventra (laquinimod)

Snippet

Status: Refused. Therapeutic area: Multiple Sclerosis. MAH: Teva Pharma GmbH. Decision date: 20/12/2013